Search Results

Discover how strategic collaboration drives real GPCR drug discovery impact. In GPCR drug discovery, where complexity is the rule and timelines are tight, this kind of cross-functional

Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics and drug discovery innovation. << Back to podcast list Dr. discovery. Ajay reveals how humility, curiosity, and collaboration fuel the future of drug discovery. Seeing the limits of traditional drug discovery, he later co-founded Superluminal Medicines, a company

self-sustaining computational chemistry service provider, developing its own software for application in various drug discovery campaigns. I have extensive training in computer-aided drug design. training as a chemist and as an entrepreneur to grow a sustainable service and software provider in drug discovery.

GPCR Podcast Strategic Partners Hacking GPCRs: Tools, Tech & Drug Discovery with Tom Sakmar & Ilana Kotliar This could accelerate discovery of therapeutic targets by combining multiplex data with focused downstream multiplex strategy aligns perfectly with this evolution, providing scalable approaches to biological discovery ________ Key Takeaway This episode is more than a conversation — it’s a masterclass in tool-driven discovery and Rockefeller University professor dedicated to drug discovery and chemical biology research, mainly

Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused spent significant time in the industry studying membrane proteins, antibodies, and HTS methods for drug discovery.

Master irreversible kinetics, target depletion, and structured tissue penetration in real drug discovery Home → Flash News → irreversible drugs post 3 Irreversible kinetics = strategic lever in drug design. strategic levers that shape how molecules behave in vivo and whether candidates advance or stall in discovery These lessons bridge molecular pharmacology with real-world design strategy, giving discovery teams the Join to learn the same principles guiding successful drug programs today. 🟢 Browse the full video vault

behavior, non-linear PK ✅ Early Drug Safety – Toxicity risks & drug interactions 📌 Spots are filling Sign up today 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. , non-linear PK✅ Early Drug Safety – Toxicity risks & drug interactions 📌 Spots are filling fast! discovery often assumes receptor inhibition follows simple rules—agonist binds, antagonist blocks, and GPCR Podcast 4 days ago Molecular creativity in drug discovery Most pharmacologists are trained to chase

Kenakin shows how experimental snapshots can reveal much more—and how predictive frameworks guide modern drug discovery. 🟢 Built for pharmacologists building stronger pipelines and those rethinking legacy models

GPCR to expand fluorescent ligand tools for GPCR drug discovery, connecting biotech startups and scientists Learn more about new ligands and new GPCR behaviors that produce unique drug profiles. Learn more about new ligands and new GPCR behaviors that produce unique drug profiles. ✳️ Last chance

established GPCR structural biology and learned the ins and outs of molecular pharmacology and in vitro drug discovery. Icahn School of Medicine at Mount Sinai in NYC, where I have been working on structure-function and drug discovery of GPCRs and transporters.

interested in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the As a young researcher fascinated by chemokine receptors, molecular pharmacology, drug discovery, and GPCR About John Azietaku John Teye Azietaku,PhD is a trained pharmacist, holding a Ph.D. in Drug Discovery discovery program.

with numerous pharma and biotechs in understanding and applying in vitro pharmacology data to advance drug discovery. He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development He guided the in vitro biology efforts of the company for numerous drug discovery campaigns.

His current focus is to realise Antiverse’s mission: engineering the future of drug discovery." Murat Tunaboylu on the web Antiverse DSV Future of Drug Discovery Podcast Twist Bioscience LinkedIn Twitter

pharmacology into creating this essential resource, designed to meet you exactly where you are in your drug discovery journey. Bridge theory to practical drug development decisions?

Featured Appearances Aug 2020 — Featured on 17 Minutes of Science with Advancing GPCR Drug Discovery Mar 2022 — Media Partner at GPCR Targeted Drug Discovery Summit . Discovery Summit . Community Engagement Mar 2024 — Media Partner at 3rd GPCR Targeted Drug Discovery Summit . Oct 2024 — Media Partner at Discovery on Target .

As a young researcher fascinated by chemokine receptors, molecular pharmacology, drug discovery, and interested in using G-Protein Coupled Receptors (GPCRs), that control virtually everything in the body, as drug GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the

Chris Langmead is Professor, Deputy Director, and Better Medicines Theme Leader of the Neuromedicines Discovery ) and is the co-founder and CEO of Phrenix Therapeutics, a biotech spin-out from the Neuromedicines Discovery Therapeutics Ltd., a UK-based biotechnology company (2009-2012), where he was responsible all of the company’s discovery He is an acknowledged expert in drug discovery, particularly in the field of psychiatry, where he has He has published over 70 research articles, reviews and book chapters on drug discovery, which have been

Principles of Pharmacology in Drug Discovery I Techniques for Effective Lead Optimization of Candidate essential pharmacologic techniques and knowledge required to create a GPCR Target Program aimed at the discovery of new Drugs. The required elements of a comprehensive and effective GPCR Discovery. Modules: October 3rd: GPCR Project Initiation and Design for Discovery of New Molecules.

scientist, biotech innovator, or industry professional, GPCR Weekly News keeps you connected to the discoveries Latest Research Breakthrough discoveries, new publications, and cutting-edge GPCR research insights. This week’s feature goes straight to the foundation: how system-level GPCR thinking protects discovery Discovery Read Full Issue November 7 - 13, 2025 A Note from Yamina — The Next Chapter of Dr. discovery.

Next Recent Articles Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism Drug discovery often assumes receptor inhibition follows simple rules—agonist binds, antagonist blocks, and GPCR Podcast 4 days ago Molecular creativity in drug discovery Most pharmacologists are trained to chase

level of organization defines specificity in signaling, and understanding it changes how we think about drug Next Recent Articles Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism Drug discovery often assumes receptor inhibition follows simple rules—agonist binds, antagonist blocks, and GPCR Podcast 4 days ago Molecular creativity in drug discovery Most pharmacologists are trained to chase

Expert support, trusted CROs, and ready-to-use tools to accelerate GPCR drug discovery, reduce risk, and advance your discovery-stage projects. GPCR Foundry: Accelerate GPCR Drug Discovery Move from idea to insight—faster, smarter, and with confidence GPCR Foundry is a nonprofit platform designed to help biotech leaders accelerate GPCR drug discovery Let's move your GPCR discovery program forward.

Discover how enzyme inhibition can enhance drug discovery strategies. This week’s Weekly News is your practical guide to building enzyme inhibition into discovery—not as a

discovery. discovery assays. Pivoting: From Chemistry Company to Discovery Partner Initially focused on tool production, Celtarys Whether you're designing assays, developing probes, or seeking better tools for GPCR drug discovery, GPCR ecosystem , GPCR drug discovery , fluorescent ligands , GPCR scientist network , custom ligand development

Technology capsule: Light on aGPCR signaling and function NovoiSMART - A new platform for GPCR antibody drug discovery Abstract Developing monoclonal antibody drugs against GPCRs and other multi-pass transmembrane technology, demonstrated in the success of COVID-19 vaccines, is emerging as a promising method for antibody discovery developing highly specific antibodies for complex targets, with implications for overcoming challenges like drug

He has more than 20 years of experience in GPCR, primarily focused on drug discovery and developing new

Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and

Eleonora Comeo About this episode Eleonora Comeo is a doctoral candidate in Medicinal Chemistry and Drug Discovery in the joint program of the University of Nottingham in the UK and Monash University in Australia

GPCR collaboration at Monash shows how shared lab ecosystems can reshape innovation and accelerate drug discovery.

GPCR ecosystem , GPCR scientist network , GPCR drug discovery , GPCR training program , GPCR online course created by AI ________ About Sokhom Pin Sokhom Pin is a receptor pharmacologist with over 20 years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic targets He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general